arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Ovid Therapeutics Inc.

OVID
$2.57 ▼ -0.19 (-6.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
44 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ovid Therapeutics Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -88.3%
Op. Margin None
ROIC -7.5%
FCF / Share None
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

44-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$733.00K
↓ -88.3%
Net Income Profit after all expenses
$-16.99M
↓ -66.0%
Operating Margin Operating profit as % of sales
-80.9%
↓ -1341.1%
FCF / Share Free cash flow per share
$-0.24
↓ -37.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
32
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 44 quarters